Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 21, 2026

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Precision-guided therapy in H3K27-altered diffuse midline glioma.

Campbell J L McKay1,2, Chelsea Mayoh3,4, Phoebe Power5

  • 1The Royal Children's Hospital, Melbourne, VIC, Australia.

Nature Communications
|May 19, 2026
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spindle Epithelial Tumor With Thymus-Like Differentiation in an Infant.

Pediatrics·2026
Same author

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Nature communications·2026
Same author

Unique Challenges in Sarcoma Care for Adolescents and Young Adults.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Neuro-oncology·2026
Same author

Balancing Risk, Benefit, and Reality: Navigating Early Phase Studies in Pediatric Diffuse Midline Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Targeted Therapy for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Summary

Precision-guided therapy (PGT) shows promise for children with diffuse midline glioma (DMG). PGT improved survival outcomes, especially after tumor progression, highlighting its clinical benefit in this high-risk pediatric cancer.

Area of Science:

  • Pediatric Oncology
  • Molecular Diagnostics
  • Clinical Trials

Background:

  • High-risk pediatric cancers, including diffuse midline glioma (DMG), have limited treatment options.
  • Precision-guided therapy (PGT) has improved survival in some pediatric cancers, but its efficacy in DMG is not well-established.

Purpose of the Study:

  • To evaluate the feasibility and clinical benefit of PGT in children with H3K27-altered diffuse midline glioma (DMG).
  • To assess survival outcomes in DMG patients receiving PGT within the Australian PRSIM clinical trial.

Main Methods:

  • Prospective cohort study enrolling 68 pediatric DMG patients in the PRSIM trial (NCT03336931).
  • Comprehensive molecular profiling including whole genome sequencing (WGS) and RNAseq was performed.
  • PGT recommendations were provided, and survival analysis was conducted for eligible patients.

More Related Videos

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Main Results:

  • PGT was recommended for 74% of patients; 26% received PGT, with an overall response rate of 48%.
  • Patients receiving PGT after tumor progression showed significantly improved overall survival (p=0.007) and progression-free survival (p=0.001).
  • Median overall survival was 21.3 months for the PGT group versus 12.1 months for the non-PGT group.

Conclusions:

  • Precision-guided therapy is feasible in pediatric patients with diffuse midline glioma.
  • PGT demonstrates potential clinical benefit, particularly for patients treated after tumor progression, improving survival outcomes.